

File Number: H.F. 808
Version: First engrossment

Date: March 7, 2017

Authors: Zerwas and others

Subject: Early Periodic Screening, Diagnosis, and Treatment (EPSDT) Coverage of Stiripentol

Analyst: Randall Chun

This publication can be made available in alternative formats upon request. Please call 651-296-6753 (voice); or the Minnesota State Relay Service at 1-800-627-3529 (TTY) for assistance. Summaries are also available on our website at: www.house.mn/hrd/.

Overview

This bill provides an exception to the prohibition on the EPSDT program covering investigational drugs by allowing the program to cover stiripentol if certain criteria are met. The EPSDT program is a federal program that requires states to provide various screening and related treatment services to children enrolled in Medicaid.

Section

1 **Investigational drugs, biological products, and devices.** Amends § 256B.0625, subd. 64. Allows the EPSDT program to cover stiripentol only:

- (1) when determined to be medically necessary;
- (2) for enrollees with Dravet syndrome or certain children with Malignant Migrating Epilepsy in Infancy;
- (3) if all other covered prescription medications have been tried without successful outcomes; and
- (4) if the U.S. Food and Drug Administration has approved the treating physician's individual patient new drug application for the use of stiripentol for treatment.

Provides that the MinnesotaCare program does not cover stiripentol.